Company Description
Mangoceuticals, Inc. engages in the development, marketing, and sale of various men’s wellness products and services through a telemedicine platform in the United States.
The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand.
It also provides oral testosterone undecanoate to treat low testosterone in men and as a form of testosterone replacement therapy under the Prime brand; and access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations.
The company markets and sells its products online through its website www.MangoRX.com. The company was incorporated in 2021 and is headquartered in Dallas, Texas.
Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.
| Country | United States |
| Founded | 2021 |
| IPO Date | Mar 21, 2023 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Jacob Cohen |
Contact Details
Address: 15110 N. Dallas Parkway, Suite 600 Dallas, Texas 75248 United States | |
| Phone | 214 242 9619 |
| Website | mangoceuticals.com |
Stock Details
| Ticker Symbol | MGRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001938046 |
| CUSIP Number | 56270V106 |
| ISIN Number | US56270V1061 |
| Employer ID | 87-3841292 |
| SIC Code | 8090 |
Key Executives
| Name | Position |
|---|---|
| Jacob D. Cohen | Co-Founder, Chief Executive Officer and Chairman |
| Eugene M. Johnston | Chief Financial Officer |
| Amanda Elizabeth Hammer | Chief Operating Officer |
| Antonios Isaac | President and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2025 | 8-K | Current Report |
| Apr 17, 2025 | 8-K | Current Report |
| Apr 11, 2025 | 8-K | Current Report |
| Apr 11, 2025 | SCHEDULE 13D/A | Filing |
| Apr 8, 2025 | 8-K | Current Report |
| Apr 2, 2025 | 8-K | Current Report |
| Apr 1, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 28, 2025 | 8-K | Current Report |
| Mar 25, 2025 | 8-K | Current Report |
| Mar 20, 2025 | 10-K | Annual Report |